Back to Search
Start Over
Accelerating the development of a group A Streptococcus vaccine: an urgent public health need.
- Source :
-
Clinical & Experimental Vaccine Research . Jul2016, Vol. 5 Issue 2, p101-107. 7p. 2 Charts. - Publication Year :
- 2016
-
Abstract
- Group A Streptococcus (GAS) infections cause substantial worldwide morbidity and mortality, mostly associated with suppurative complications such as pharyngitis, impetigo, and nonsuppurative immune syndromes such as acute rheumatic fever, rheumatic heart disease, and acute post-streptococcal glomerulonephritis. Deaths occur mostly in children, adolescents, and young adults in particular pregnant women in low- and middle-income countries. GAS strains are highly variable, and a GAS vaccine would need to overcome the issue of multiple strains. Several approaches have been used multivalent vaccines using N-terminal polypeptides of different M protein; conserved M protein vaccines with antigens from the conserved C-repeat portion of the M protein; incorporation selected T- and B-cell epitopes from the C-repeat region in a synthetic polypeptide or shorter single minimal B-cell epitopes from this same region; and non-M protein approaches utilizing highly conserved motives of streptococcal C5a peptidase, GAS carbohydrate and streptococcal fibronectin-binding proteins. A GAS vaccine represents urgent need for this neglected disease and should therefore deserve the greatest attention of international organizations, donors, and vaccine manufacturers. [ABSTRACT FROM AUTHOR]
Details
- Language :
- English
- ISSN :
- 22873651
- Volume :
- 5
- Issue :
- 2
- Database :
- Academic Search Index
- Journal :
- Clinical & Experimental Vaccine Research
- Publication Type :
- Academic Journal
- Accession number :
- 118357114
- Full Text :
- https://doi.org/10.7774/cevr.2016.5.2.101